Allarity (ALLR) Stock News

Allarity Therapeutics (NASDAQ: ALLR) has announced the dosing of the second patient in its new Phase 2 clinical trial of stenoparib, a dual PARP and WNT pathway inhibitor, for treating advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.

The trial builds upon previous Phase 2 data that showed durable clinical benefit and favorable tolerability with twice-daily dosing. The study aims to evaluate stenoparib as a potential novel, targeted treatment option for patients with limited alternatives. Additionally, the trial will advance Allarity's proprietary Drug Response Predictor (DRP®) companion diagnostic and further study stenoparib's unique WNT-modulating mechanism of action.

Allarity Therapeutics (NASDAQ: ALLR) announced changes to its Board of Directors, with Jesper Høiland appointed as a new board member, replacing Joseph Vazzano effective June 30, 2025. Høiland, who has been serving as a strategic consultant to Allarity since October 2024, brings over 30 years of pharmaceutical commercialization and executive leadership experience. His background includes serving as President and EVP of Novo Nordisk's U.S. operations and as President and CEO of Radius Health. Currently, he serves as Chairman of SciBase Holding AB and board member of ALK-Abello A/S and Flen Health SA. The appointment comes as Allarity, a Phase 2 clinical-stage pharmaceutical company, continues developing stenoparib, a dual PARP and WNT pathway inhibitor, using its proprietary Drug Response Predictor technology.

Allarity Therapeutics (NASDAQ: ALLR) has announced a research collaboration with Indiana Biosciences Research Institute (IBRI) to study stenoparib's dual mechanism of action. Stenoparib is a novel oral drug that uniquely combines PARP1/2 and tankyrase1/2 inhibition, targeting both DNA repair and WNT signaling pathway in cancer cells. The collaboration aims to understand how these dual mechanisms contribute to the drug's anticancer effects, particularly in cases resistant to standard treatments. This research will support Allarity's ongoing Phase 2 trial in advanced ovarian cancer and its combination trial with temozolomide in recurrent small cell lung cancer. The partnership is expected to enhance the company's DRP-based patient selection strategy and potentially expand therapeutic applications, including colorectal cancer treatment where WNT pathway activation is common.

Allarity Therapeutics (NASDAQ: ALLR) has enrolled the first patient in a new Phase 2 clinical trial of stenoparib for advanced, platinum-resistant or platinum-ineligible ovarian cancer. The trial builds on promising data from an ongoing Phase 2 study where patients receiving twice-daily stenoparib showed durable clinical benefit and good tolerability, with two patients continuing treatment after 20+ months. The new protocol focuses on evaluating stenoparib as a potentially safer alternative to chemotherapy, incorporating the drug-specific DRP companion diagnostic. The study will explore optimal dosing aligned with FDA's Project Optimus initiative and investigate stenoparib's unique WNT pathway modulation. Significant clinical data is expected by late summer 2026, with plans to pursue expedited regulatory pathways for both stenoparib and its companion diagnostic.

Allarity Therapeutics (NASDAQ: ALLR) has announced its participation in the upcoming Pharma Partnering Summit US, scheduled for May 14-15 in San Diego. CEO Thomas Jensen will present a company overview highlighting their key assets: stenoparib, a Phase 2 dual PARP and WNT pathway inhibitor, and their DRP® companion diagnostic platform. The event serves as a business development and licensing conference for biotech and pharmaceutical executives. Jensen will be available for one-on-one meetings with registered attendees during the summit.

Allarity Therapeutics (NASDAQ: ALLR) reported its Q1 2025 financial results and operational updates. The company's lead drug stenoparib continues to show promising results in ovarian cancer treatment, with two patients maintaining treatment benefits for over 19 months. Key financial highlights include a cash balance of $27.7 million, reduced quarterly net loss of $2.7 million (vs $3.8 million in Q1 2024), and lower R&D and G&A expenses. The company has fully utilized its ATM offering and initiated a $5 million share repurchase program, with approximately 2 million shares already repurchased. Upcoming milestones include new trial enrollments for ovarian cancer and small cell lung cancer in combination with temozolomide. The company has also resolved previous SEC matters and had a class action lawsuit dismissed.

Allarity Therapeutics (NASDAQ: ALLR) has announced the presentation of a new Drug Response Predictor (DRP®) for daratumumab at the 2025 AACR Annual Meeting. The novel predictor is designed to identify multiple myeloma patients most likely to benefit from daratumumab treatment.

The DRP® was developed by analyzing gene expression patterns correlated with daratumumab sensitivity, identifying 53 genes - 27 associated with sensitivity and 26 with resistance. Using data from the KYDAR trial, the DRP demonstrated ability to predict treatment outcomes and survival in multiple myeloma patients.

This marks Allarity's first DRP® developed for an antibody therapy, expanding beyond their previous small-molecule drug predictors. The company currently has stenoparib, a dual PARP and WNT pathway inhibitor, in Phase 2 development for ovarian cancer and small cell lung cancer.

Allarity Therapeutics (NASDAQ: ALLR) reported its full year 2024 financial results, highlighting a strong cash position of $20.9 million as of December 31, 2024, with approximately $25 million at Q1 2025 end. This funding is expected to support operations into 2027.

The company's primary focus is on stenoparib, their dual PARP/WNT pathway inhibitor, which showed promising results in treating heavily pre-treated ovarian cancer patients, with some patients maintaining treatment benefits for over 17 months. Two key clinical trials are planned: a Phase 2 ovarian cancer trial starting H1 2025, and a VA-funded Phase 2 SCLC combination trial beginning Q2-Q3 2025.

Financial highlights include:

• R&D expenses: $6.1 million (down from $7.1 million in 2023)
• G&A expenses: $11.4 million (up from $10.0 million in 2023)
• Net loss: $24.5 million (increased from $11.9 million in 2023)
• Fully utilized ATM program and implemented a $5 million share repurchase program

Allarity Therapeutics (NASDAQ: ALLR) has announced a strategic partnership with Shareholder Intelligence Services (ShareIntel) to investigate potential illegal naked short selling and trading irregularities in its stock. The initiative aims to protect shareholder value and ensure transparent trading practices.

ShareIntel will employ its proprietary DRIL-Down™ technology to analyze trading patterns, monitor potential abuses, and detect unusual short-selling activities. The platform will track data from broker-dealers, clearing firms, and reporting entities to identify possible market manipulation.

The company, currently in Phase 2 clinical trials developing stenoparib (a dual PARP/Wnt pathway inhibitor), will specifically monitor compliance with SEC's Regulation SHO regarding short-selling practices. If violations are detected, Allarity plans to pursue legal action against responsible parties.